Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 6
2022 5
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Advanced and recurrent endometrial cancer: State of the art and future perspectives.
Tronconi F, Nero C, Giudice E, Salutari V, Musacchio L, Ricci C, Carbone MV, Ghizzoni V, Perri MT, Camarda F, Gentile M, Berardi R, Scambia G, Lorusso D. Tronconi F, et al. Among authors: giudice e. Crit Rev Oncol Hematol. 2022 Dec;180:103851. doi: 10.1016/j.critrevonc.2022.103851. Epub 2022 Oct 17. Crit Rev Oncol Hematol. 2022. PMID: 36257537 Review.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
PARP Inhibitors Resistance: Mechanisms and Perspectives.
Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D. Giudice E, et al. Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420. Cancers (Basel). 2022. PMID: 35326571 Free PMC article. Review.
Management of stage III and IVa uterine cancer.
Nero C, Tronconi F, Giudice E, Scambia G, Lorusso D. Nero C, et al. Among authors: giudice e. Int J Gynecol Cancer. 2022 Mar;32(3):316-322. doi: 10.1136/ijgc-2021-002554. Int J Gynecol Cancer. 2022. PMID: 35256418 Review.
Pembrolizumab for advanced cervical cancer: safety and efficacy.
De Felice F, Giudice E, Bolomini G, Distefano MG, Scambia G, Fagotti A, Marchetti C. De Felice F, et al. Among authors: giudice e. Expert Rev Anticancer Ther. 2021 Feb;21(2):221-228. doi: 10.1080/14737140.2021.1850279. Epub 2020 Nov 26. Expert Rev Anticancer Ther. 2021. PMID: 33183120 Review.
Recent progress in the use of pharmacotherapy for endometrial cancer.
Giudice E, Salutari V, Ricci C, Nero C, Carbone MV, Musacchio L, Ghizzoni V, Perri MT, Camarda F, Tronconi F, Lorusso D, Scambia G. Giudice E, et al. Expert Opin Pharmacother. 2023 Jan;24(1):83-94. doi: 10.1080/14656566.2022.2106782. Epub 2022 Aug 5. Expert Opin Pharmacother. 2023. PMID: 35912837 Review.
Secondary cytoreduction for relapsed ovarian cancer.
Iannantuono GM, Giudice E. Iannantuono GM, et al. Among authors: giudice e. Lancet Oncol. 2021 Jun;22(6):e232. doi: 10.1016/S1470-2045(21)00277-1. Lancet Oncol. 2021. PMID: 34087141 No abstract available.
19 results